Racial disparity in the use of atypical antipsychotic medications among veterans

American Journal of Psychiatry

Volumn 160, Issue 10, 2003, Pages 1817-1822

  Copeland, Laurel A ^a   Zeber, John E ^b   Valenstein, Marcia ^b   Blow, Frederic C ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; OLANZAPINE; PIRENZEPINE; QUETIAPINE; RISPERIDONE;

AFRICAN AMERICAN; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; HISPANIC; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RACE DIFFERENCE; SCHIZOPHRENIA; SOLDIER; SUBSTANCE ABUSE; CAUCASIAN; ETHNIC GROUP; ETHNOLOGY; STATISTICS; UNITED STATES; VETERAN;

AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; MULTIVARIATE ANALYSIS; PIRENZEPINE; PRESCRIPTIONS, DRUG; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES; VETERANS;

EID: 0642309949     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.10.1817     Document Type: Article

References (43)

1. Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002; 159:567-572
2. Davidson JR, Raft D, Lewis BF, Gebhardt M: Psychotropic drugs on general medical and surgical wards of a teaching hospital. Arch Gen Psychiatry 1975; 32:507-511
3. Lasser KE, Himmelstein DU, Woolhandler SJ, McCormick D, Bor DH: Do minorities in the United States receive fewer mental health services than whites? Int J Health Serv 2002; 32:567-578
4. Briones DF, Heller PL, Chalfant HP, Roberts AE, Aguirre-Hauchbaum SF, Farr WF Jr: Socioeconomic status, ethnicity, psychological distress, and readiness to utilize a mental health facility. Am J Psychiatry 1990; 147:1333-1340
5. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949-958
6. Dassori AM, Miller AL, Saldana D: Schizophrenia among Hispanics: epidemiology, phenomenology, course, and outcome. Schizophr Bull 1995; 21:303-312
7. Escobar JI, Karno M, Burnam A, Hough RL, Golding J: Distribution of major mental disorders in a US metropolis. Acta Psychiatr Scand Suppl 1988; 344:45-53
8. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
9. Adebimpe VR: Overview: white norms and psychiatric diagnosis of black patients. Am J Psychiatry 1981; 138:279-285
10. Jones BE, Katz ND: Madness and addiction: treating the mentally ill chemical abuser. J Health Care Poor Underserved 1992; 3:39-45
11. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M: Racial differences in the diagnosis of psychosis. Schizophr Res 1996; 21:17-24
12. Neighbors HW, Jackson JS, Campbell L, Williams D: The influence of racial factors on psychiatric diagnosis. Community Ment Health J 1989; 25:301-311
13. Whaley AL: Racism in the provision of mental health services: a social-cognitive analysis. Am J Orthopsychiatry 1998; 68:47-57
14. Zeber JE, Blow FC, Valenstein M, McCarthy JF, Gillon L, Bingham CR: Ethnicity and diagnostic disparity in veterans with psychoses, in Proceedings of the 2003 National Meeting of Health Services Research and Development. Veterans Health Administration Health Services Research and Development, Washington, DC, 2003
15. Rossiter LF: Prescribed medicines: findings from the National Medical Care Expenditure Survey. Am J Public Health 1983; 73:1312-1315
16. Price N, Glazer W, Morgenstern H: Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry 1985; 142:1491-1492
17. Sellwood W, Tarrier N: Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994; 29:172-177
18. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S: Adherence assessments and the use of depot antipsychotic medications in patients with schizophrenia. J Clin Psychiatry 2001; 62:545-554
19. Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24:11-20
20. Segal SP, Bola JR, Watson MA: Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996; 47:282-286
21. Ruiz S, Chu P, Sramek J, Rotavu E, Herrera J: Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med 1996; 63:306-309
22. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile, and impact on quality of life. Schizophr Res 2000; 43:135-145
23. Mark TL, Dirani R, Slade E, Russo PA: Access to new medications to treat schizophrenia. J Behav Health Serv Res 2002; 29:15-29
24. Lehman AF, Steinwachs DM: At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24:1-10
25. Tran PV, Lawson WB, Andersen S, Shavers E: Treatment of the African-American patient with novel antipsychotic agents, in Cross Cultural Psychiatry. Edited by Herrera JM, Lawson WB, Sramek JF. Chichester, UK, John Wiley & Sons, 1999, pp 131-138
26. Moeller FG, Chen YW, Steinberg JL, Petty F, Ripper GW, Shah N. Garver DL: Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995; 7:167-173
27. Lawson WB: The art and science of the psychopharmacotherapy of African Americans. Mt Sinai J Med 1996; 63:301-305
28. Harada ND, Damron-Rodriguez J, Villa VM, Washington DL, Dhanani S, Shon H, Chattapadhyay M, Fishbein H, Lee M, Makinodan T, Andersen R: Veteran identity and race/ethnicity: influences on VA outpatient care utilization. Med Care 2002; 40:1117-1128
29. Strauss GD, Sack DA, Lesser I: Which veterans go to VA psychiatric hospitals for care: a pilot study. Hosp Community Psychiatry 1985; 36:962-965
30. Blow FC, McCarthy JF, Valenstein M, Zeber JE, Leibfried T, Gillon L: Care in the VHA for Veterans With Psychosis 1999. Veterans Health Administration Health Services Research and Development, Ann Arbor, Mich., 2000
31. Blow FC, McCarthy JF, Valenstein M, Zeber JE, Gillon L: Care in the VHA for Veterans With Psychoses 2000: National Psychoses Registry: 2nd Annual Report. Veterans Health Administration Health Services Research and Development, Ann Arbor, Mich., 2001
32. Rosenheck R, Fontana A: Utilization of mental health services by minority veterans of the Vietnam era. J Nerv Ment Dis 1994; 182:685-691
33. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE: Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58:108-111
34. Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77-89
35. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566
36. Black SA: Diabetes, diversity, and disparity: what do we do with the evidence? Am J Public Health 2002; 92:543-548
37. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer H, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care 1998; 21:518-524
38. Buckley PF: Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998; 59(suppl):26-30
39. Drake RE, Xie H, McHugo GJ, Green AI: The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26:441-449
40. Drake RE, Mueser KT, Clark RE, Wallach MA: The course, treatment, and outcome of substance disorder in persons with severe mental illness. Am J Orthopsychiatry 1996; 66:42-51
41. Strickland TL, Ranganath V, Lin K-M, Poland RE, Mendoza R, Smith MW: Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull 1991; 27:441-448
42. VA Health Care: Implementation of Prescribing Guideline for Atypical Antipsychotic Drugs Generally Sound. Washington, DC, General Accounting Office, 2002
43. Kasper S, Muller-Spahn F: Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1:783-801